<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722887</url>
  </required_header>
  <id_info>
    <org_study_id>GC2008</org_study_id>
    <nct_id>NCT04722887</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency</brief_title>
  <official_title>A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subjects With Alpha1-Antitrypsin Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per&#xD;
      kilogram (mg/kg) and 144 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC)&#xD;
      infusion and subsequently as weekly SC infusions over 8 weeks in participants with&#xD;
      Alpha1-Antitrypsin Deficiency (AATD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">February 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 5, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Up to 252 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Suspected Adverse Drug Reactions (ADRs)</measure>
    <time_frame>Up to 252 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Infusion Site Reactions</measure>
    <time_frame>Up to 252 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 252 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With AEs and SAEs Leading to Discontinuation</measure>
    <time_frame>Up to 252 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations</measure>
    <time_frame>Up to 252 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate, and Temperature)</measure>
    <time_frame>Up to 252 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Up to 252 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Forced Vital Capacity (FVC)</measure>
    <time_frame>Up to 252 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters (Chemistry, Hematology, Urinalysis)</measure>
    <time_frame>Up to 252 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: Number of Participants With Alpha1-PI Antibodies</measure>
    <time_frame>Treatment Period 1- Single-Dose Week 1; Treatment Period 2- Repeat-Dose Weeks 1 and 9</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Alpha1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Alpha-1 15% 72 mg/kg, single weekly subcutaneous (SC) infusion in treatment-period 1 (Single-Dose) at Week 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following treatment period 1, participants in Cohort 1 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation period. During the single-dose data evaluation phase, Liquid Alpha1- Proteinase Inhibitor (PI) 60 mg/kg, weekly intravenous (IV) Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 20, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following treatment period 1 and single-dose data evaluation period, participants in Cohort 1 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 72 mg/kg, for 8 weekly SC infusions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Treatment Period 1 (Alpha-1 15%, 144 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Alpha-1 15% 144 mg/kg, single weekly SC infusion in treatment-period 1 (Single-Dose) at Week 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following treatment period 1, participants in Cohort 2 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation phase. During the single-dose data evaluation phase, Liquid Alpha1-PI 120 mg/kg, weekly IV Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 20, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Treatment Period 2 (Alpha-1 15%, 144 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following treatment period 1 and single-dose data evaluation phase, participants in Cohort 2 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 144 mg/kg, for 8 weekly SC infusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alpha-1 15%</intervention_name>
    <description>Alpha1-Proteinase Inhibitor (Human), 15%, Subcutaneous infusion</description>
    <arm_group_label>Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 2: Treatment Period 1 (Alpha-1 15%, 144 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 2: Treatment Period 2 (Alpha-1 15%, 144 mg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Liquid Alpha1-Proteinase Inhibitor (Human)</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)</arm_group_label>
    <other_name>Prolastin®-C Liquid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of congenital Alpha1-antitrypsin deficiency (AATD) with an allelic&#xD;
             combination of ZZ, SZ, Z(null), (null)(null), S(null), or &quot;at-risk&quot; alleles (subjects&#xD;
             with &quot;at-risk&quot; alleles must be individually evaluated for eligibility by the Medical&#xD;
             Monitor).&#xD;
&#xD;
          -  Have a documented pre-Alpha1-Proteinase Inhibitor (PI) augmentation therapy serum&#xD;
             alpha-1 antitrypsin (AAT) level &lt;11 micrometer (μM) (80 milligrams per decilitre&#xD;
             (mg/dL) if measured by radial immunodiffusion or 50 mg/dL if measured by&#xD;
             nephelometry).&#xD;
&#xD;
          -  Currently receiving Alpha1-PI augmentation therapy or has received Alpha1-PI&#xD;
             augmentation therapy within the past. If the subject is currently receiving Alpha1-PI&#xD;
             augmentation therapy of any kind, he/she must be willing to discontinue that treatment&#xD;
             at the Week 1 (Baseline) Visit and remain off any kind of Alpha1-PI treatment, other&#xD;
             than the IPs for this study, while participating in the study. Note: Subjects must not&#xD;
             be naïve to Alpha1-PI augmentation therapy for study participation.&#xD;
&#xD;
          -  At the Screening Visit, have a post-bronchodilator forced expiratory volume (FEV1)&#xD;
             ≥30% and &lt;80% of predicted and FEV1/forced vital capacity (FVC) &lt;70% (Global&#xD;
             Initiative for Chronic Obstructive Lung Disease (GOLD) stage II or III).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have had a moderate or severe Chronic obstructive pulmonary disease (COPD)&#xD;
             exacerbation during the 4 weeks before the Week 1 (Baseline) Visit.&#xD;
&#xD;
          -  Have history of lung or liver transplant.&#xD;
&#xD;
          -  Have any lung surgery during the past 2 years (excluding lung biopsy).&#xD;
&#xD;
          -  Have severe concomitant disease (example, congestive heart failure, clinically&#xD;
             significant pulmonary fibrosis, malignant disease [except for skin cancers other than&#xD;
             melanoma], history of acute hypersensitivity pneumonitis reaction, or current chronic&#xD;
             hypersensitivity pneumonitis).&#xD;
&#xD;
          -  Females who are pregnant, breastfeeding or, if of child-bearing potential, unwilling&#xD;
             to practice a highly effective method of contraception (oral, injectable, or implanted&#xD;
             hormonal methods of contraception, placement of an intrauterine device (IUD) or&#xD;
             intrauterine system (IUS), condom or occlusive cap with spermicidal&#xD;
             foam/gel/film/cream/suppository, male sterilization, or true abstinence) throughout&#xD;
             the study.&#xD;
&#xD;
          -  Have smoked during the past 6 months or a positive urine cotinine test at the&#xD;
             Screening Visit that is due to smoking.&#xD;
&#xD;
          -  Participate in another Investigational product (IP) study within one month prior to&#xD;
             the Week 1 (Baseline) Visit.&#xD;
&#xD;
          -  Have history of anaphylaxis or severe systemic response to any plasma-derived&#xD;
             Alpha1-PI preparation or other blood product(s).&#xD;
&#xD;
          -  Use systemic steroids above a stable dose equivalent to 5 mg/day prednisone (i.e., 10&#xD;
             mg every 2 days) within the 4 weeks prior to the Week 1 (Baseline) Visit. It is&#xD;
             recommended to maintain the same dose throughout the study.&#xD;
&#xD;
          -  Use systemic or aerosolized antibiotics for a chronic COPD exacerbation within the 4&#xD;
             weeks prior to the Week 1 (Baseline) Visit.&#xD;
&#xD;
          -  Have known selective or severe Immunoglobulin A (IgA) deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rhonda Griffin</last_name>
    <phone>+1 919 316 6693</phone>
    <email>rhonda.griffin@grifols.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim Steinmann</last_name>
    <phone>+1 919-316-2245</phone>
    <email>kimberly.steinmann@grifols.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse West</last_name>
    </contact>
    <investigator>
      <last_name>Jorge Lascano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen McCutcheon</last_name>
    </contact>
    <investigator>
      <last_name>Jason Thomason, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Villarreal</last_name>
    </contact>
    <investigator>
      <last_name>Ather Siddiqi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Emphysema</keyword>
  <keyword>Alpha-1 Antitrypsin Deficiency</keyword>
  <keyword>AATD</keyword>
  <keyword>Alpha-1 PI Deficiency</keyword>
  <keyword>Alpha-1 Proteinase Inhibitor</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Pulmonary Disease, Chronic Obstructive</keyword>
  <keyword>Lung Diseases, Obstructive</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Subcutaneous Emphysema</keyword>
  <keyword>Alpha1-Antitrypsin</keyword>
  <keyword>Trypsin Inhibitors</keyword>
  <keyword>Serine Proteinase Inhibitors</keyword>
  <keyword>Protease Inhibitors</keyword>
  <keyword>Enzyme Inhibition</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

